Clinical Trial Update: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC [Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 2 study evaluating sequencing of antibody-drug conjugates in estrogen receptor-positive, HER2-low/ultra-low metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Low Breast Cancer

Snippet

Sponsor: Reshma L. Mahtani, D.O. | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING